Gene therapy for solid tumors that returned after treatment
Treatments studied
Part of Cancer clinical trials.
This trial tests a new type of gene therapy that uses your own immune cells (called myeloid cells) engineered to produce a protein (IL-12) to fight your cancer. It is for people with solid tumors that have not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor cancer that has returned or not responded to standard treatments.
- You are 18 years or older and able to walk or sit in a wheelchair independently.
- You have adequate organ function, such as acceptable blood counts, liver, kidney, and heart function.
- You are willing to have tumor biopsies (tissue samples) taken before and after treatment.
- You have had at least one prior cancer treatment.
- You must avoid pregnancy or fathering a child for a period after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new therapy that uses your own immune cells (called TILs) to fight advanced solid tumors. The cells are taken from a tumor, grown in a lab, and then given back to you, potentially helping your body attack the cancer.
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
This trial tests a new treatment made from your own immune cells (called tumor-infiltrating lymphocytes) that are genetically modified to fight cancer better. It is for people with certain advanced solid tumors that have not responded well to other treatments.
This study tests a new treatment that uses your own immune cells, called TIL, to fight advanced solid tumors. It may be given alone or with another drug that helps the immune system attack cancer. The goal is to see if this treatment is safe and effective for people who have already tried other treatments.
This trial tests a new gene therapy that re-engineers your own immune cells to attack CD19-positive lymphoma. It is for people whose B-cell lymphoma has come back or not responded to at least two standard treatments.
This trial tests a personalized therapy made from your own immune cells (TIL) picked to match your tumor’s “neoantigens,” plus standard immune-boosting medicine (including IL-2). It’s for people with advanced epithelial or immune “resistant” solid tumors whose cancer has continued growing despite available treatments.
Hear when a new Relapsed Solid Tumor Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.